• 227%

    CA 15.3

    Predicting early recurrence in women treated for Carcinoma Breast

    CA 15.3

    Predicting early recurrence in women treated for Carcinoma Breast
  • 227%

    CA 19-9

    Monitoring the response to treatment and recurrence of Pancreatic Cancer

    CA 19-9

    Monitoring the response to treatment and recurrence of Pancreatic Cancer
  • 227%

    CALCIUM – URINE

    Calcium in urine

    CALCIUM – URINE

    Calcium in urine
  • 228%

    CALCIUM IONISED (CA++)

    Accurate assessment of calcium especially in the presence of high protein concentrations, hyperparathyroidism or hypoparathyroidism

    CALCIUM IONISED (CA++)

    Accurate assessment of calcium especially in the presence of high protein concentrations, hyperparathyroidism or hypoparathyroidism
  • 228%

    Calcium; Total

    Assessment of parathyroid function test

    Calcium; Total

    Assessment of parathyroid function test
  • 228%

    Cancer Antigen (CA) 27.29

    Monitoring the response to treatment and recurrence in women with Stage II or III Breast cancer

    Cancer Antigen (CA) 27.29

    Monitoring the response to treatment and recurrence in women with Stage II or III Breast cancer
  • 229%

    Carbamazepine

    Monitoring Carbamazepine therapy in uremic patients

    Carbamazepine

    Monitoring Carbamazepine therapy in uremic patients
  • 229%

    Carcino Embryonic Antigen (CEA ...

    Establish a baseline for evaluating possible recurrence before starting therapy in primary colorectal carcinoma

    Carcino Embryonic Antigen (CEA ...

    Establish a baseline for evaluating possible recurrence before starting therapy in primary colorectal carcinoma
  • 229%

    CARNITINE

    Evaluation of patients with a clinical suspicion of a wide range of inborn errors of metabolism

    CARNITINE

    Evaluation of patients with a clinical suspicion of a wide range of inborn errors of metabolism